Akari Therapeutics plc ADS (AKTX)
Stock · NASDAQ · Health Care
$8.18as of 10/16/2026
Price chart
Active signals
AKTX Signal Track Record
How signals performed across all stocks →What AKTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 24 | -12.3% | 29% | May 12, 2026 |
| Bollinger Band Breakout | 16 | -4.1% | 44% | August 26, 2026 |
| Volume Spike | 9 | -6.3% | 44% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -20.9% | 25% | September 30, 2026 |
| Any 20-session window (baseline) | -10.0% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AKTX
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer typ…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- www.akaritx.com/
Fundamentals
- 1-day range
- $8.03$8.66
- Market cap
- $14.14M
- P/E (trailing)
- Infinity
- P/E (forward)
- -0.95
- EPS (trailing)
- $-0.00
- Dividend yield
- —
- Beta
- 1.48
- Avg. volume
- 62.0K
Forecasts
3 analyst ratings
Akari Therapeutics plc ADS Competitors
Chosen by industry and closest market cap.
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
- COCPCocrystal Pharma Inc. Common Stock$1.02▼ 0.97%Market cap $14.20MP/E —$0.76$2.03
- KALAKALA BIO Inc. Common Stock$0.19▼ 1.04%Market cap $14.25MP/E —$0.2593$95.5
- PTNPalatin Technologies Inc. Common Stock$6.02▼ 7.24%Market cap $14.00MP/E 92.55$5.61$31
- TPSTTempest Therapeutics Inc. Common Stock$0.624▼ 1.73%Market cap $14.42MP/E —$0.6801$12.23
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
- KTTAPasithea Therapeutics Corp. Common Stock$0.42▲ 2.44%Market cap $14.82MP/E —$0.281$2.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
| COCP Cocrystal Pharma Inc. Common Stock | $14.20M | — | $1.02 | ▼ 0.97% | $0.76$2.03 |
| KALA KALA BIO Inc. Common Stock | $14.25M | — | $0.19 | ▼ 1.04% | $0.2593$95.5 |
| PTN Palatin Technologies Inc. Common Stock | $14.00M | 92.55 | $6.02 | ▼ 7.24% | $5.61$31 |
| TPST Tempest Therapeutics Inc. Common Stock | $14.42M | — | $0.624 | ▼ 1.73% | $0.6801$12.23 |
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
| KTTA Pasithea Therapeutics Corp. Common Stock | $14.82M | — | $0.42 | ▲ 2.44% | $0.281$2.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in CancersYahoo · 10/1/2026
- Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP PortfolioBenzinga · 10/1/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/15/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Abizer Gaslightwala · September 29, 2026 · Grant6.4K @ $9.72
- Kameel D. Farag · August 17, 2026 · Grant1.7K @ $7.52
- Kameel D. Farag · July 16, 2026 · Grant1.1K @ $11.5
- Samir Rashmikant Patel · July 7, 2026 · Option Exercise5.8K @ $0.0004
- Samir Rashmikant Patel · July 7, 2026 · Option Exercise15.5K @ $0.0004
- Samir Rashmikant Patel · July 7, 2026 · Option Exercise1.2K @ $8
- Kameel D. Farag · June 24, 2026 · Grant1.0K @ $13
- Kameel D. Farag · June 24, 2026 · Grant7.4K @ $3.74
- Kameel D. Farag · June 24, 2026 · Grant3.7K @ $3.49
- Kameel D. Farag · June 24, 2026 · Grant2.5K @ $5.12
- Kameel D. Farag · June 24, 2026 · Grant1.6K @ $8.28
- Kameel D. Farag · June 24, 2026 · Grant1.4K @ $9.32
- Kameel D. Farag · June 24, 2026 · Grant1.2K @ $10.02
- Abizer Gaslightwala · June 24, 2026 · Grant15.6K
- Abizer Gaslightwala · June 24, 2026 · Grant5.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 59.7K
- Total value held
- $307.3K
- Institutional holders
- 6
- Unknown38.9K
- Unknown20.6K
- Unknown181
- Unknown5
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application
Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.